Research Papers
The Research Paper series is a series of research reports compiled for each research theme.
Please note that some of the links in the past papers may be broken.
-
The Actual Use of Real World Data in the Pharmaceutical Industry as Seen in Academic Papers
(No.85: Published in March, 2025) -
Development of Digital Medicine and Utilization of Health Care Data
-The Pharmaceutical Industry in the Age of Medical and Health Care Transformation-.
(No.84: Issued in March 2024) -
Toward a NHI and drug pricing system that is highly convincing to the public
(No.83: Issued Mar. 2024) -
Actual Conditions of Pharmaceutical R&D
~Research and Development Duration, Probability of Success, and R&D Costs Based on Questionnaire Survey~.
(No.82: Issued in Mar. 2024) -
The Actual Situation and Prospects for Co-Creation Drug Discovery Centered on Academia, Drug Discovery Ventures, and Pharmaceutical Companies
(No.81: Issued in Oct. 2023) -
Toward Data-Driven R&D
-Thinking about the utilization of health and medical data- (No.80: October 2023)
(No.80: Issued in March 2022) -
Diverse Values of Pharmaceuticals
-Consideration from the Public's Perspective and in Light of Changes in the Healthcare Environment
(No.79: To be issued in March 2022) -
Advancement of Digital Technology and Paradigm Shift in Medical Health Care
Toward the realization of data-driven healthcare
(No.78: Jul. 2021 issue) -
Research on Introduction and Construction of Next Generation Drug Discovery Platform Technology
(No.77: Published May 2021) -
Multidimensional Evaluation of the Social Value of Pharmaceuticals
(No.76: Issued Mar. 2021) -
Re-thinking the "Value of Pharmaceuticals" from the Patient's Perspective
Toward a Virtuous Circle of Drug Discovery, Drug Development, and Active Pharmaceutical Ingredients
(No.75: To be issued in June 2020) -
Structure and Dynamics of Drug Pricing in Japan, the U.S., and Europe: Reflecting Innovation
(No.74: October 2019) -
A New Look at the "Value of Pharmaceuticals"
(No.73: May 2019 issue) -
The Future of Small Molecular Drugs from the Aspect of Drug Discovery Chemistry
Expanding from Small to Medium Molecules
(No.72: May 2018 issue) -
Challenges and Recommendations for Further Development of the Biopharmaceutical Industry
(No.71: Published Mar 2018) -
Study on the Current Status of Orphan Drug Designation Requirements in Japan
A Study Based on a Questionnaire Survey of Pharmaceutical Companies
(No.70: Published in Mar 2017) -
Clinical Development and Approval Review of New Drugs in Japan
Items approved from 2000 to 2015
(No.69: Published in Nov. 2016) -
Clinical Development and Approval Review of New Drugs in Japan
Items Approved 2000-2014
(No.68: Published November 2015) -
Clinical Development and Science Survey on Scientific Sources of Pharmaceutical Innovation and Their Economic Impact (2)
(No.67: Published in August 2015) -
Exploratory Research and Science Survey on Scientific Sources of Pharmaceutical Innovation and Their Economic Impact (1)
(No.66: Published in August 2015) -
A Study on the Attitude Gap in Alliances between Pharmaceutical Companies and Venture Capitalists
(No. 65: Issued 05/2015) -
A Study on the Application of Patient Reported Outcome to New Drug Development in Promoting Patient-Centered
(No.64: Published March 2015) -
Clinical Development and Approval Review of New Drugs in Japan
Items Approved 2000-2013
(No.63: Published November 2014) -
Clinical Development and Review of New Drugs in Japan
New Drugs Approved in Japan 2000-2012
(No.62: Issued in January 2014) -
Effects of Policies to Promote the Use of Generic Drugs
(No.61: Issued November 2013) -
Survey on the Current Status of Physicians' Clinical Trial Initiatives
From the results of a survey of physicians in charge of clinical trials in Japan, South Korea, and the U.S.
(No.60: Published in August 2013) -
Duration and Cost of Drug Development
A survey of the actual situation through questionnaires
(No.59: Issued Jul. 2013) -
Japan's Excess of Drug Imports and Challenges in Drug Discovery Infrastructure
(No.58: Issued Apr. 2013) -
The Role of Biomarkers in Drug Development
(No.57: March 2013 issue) -
Current Status and Prospects of Personalized Medicine in Drug Therapy
Impact of Advances in Basic Research on Drug Development
(No.56: March 2013 issue) -
Clinical Development and Approval Review of New Drugs in Japan
Items Approved from 2000 to 2011
(No.55: November 2012 issue) -
Promotion of Generic Drug Use and Market Impact
(No.54: June 2012) -
The Actual Situation and Challenges of Business Risk Management in Pharmaceutical Companies
(No.53: March 2012 issue) -
Taxation as an Environment for International Competitiveness and Drug Discovery in the Pharmaceutical Industry
Contribution of the Domestic Pharmaceutical Industry to the Structural Transformation to a High Value-Added Economy
(No.52: March 2012 issue) -
Clinical Development and Approval Review of New Drugs in Japan 2000-2010 Approved Drugs
(No.51: Published in November 2011) -
Clinical Development and Review of New Drugs in Japan
New Drugs Approved in Japan 2000-2009
(No.50: Issued in September 2010) -
International Competitiveness and Growth Strategies of R&D-Based Pharmaceutical Companies
(No.49: March 2010 issue) -
Alliances between Pharmaceutical Companies and Bio-ventures
A Comparative Analysis of Japanese, U.S. and European Pharmaceutical Companies
(No.48: Published November 2009) -
Clinical Development and Approval Review of New Drugs in Japan
(No.47: October 2009) -
Challenges for Japan in streamlining the drug discovery process based on trends in patent applications in the field of biomarker-related research
(No.46: Published October 2009) -
Drug Pipelines and Pharmaceutical Licensing
(No.45: Issued in April 2009) -
Questionnaire Survey of Pharmaceutical Companies on Pharmacoeconomic Evaluation
(No.44: Published December 2008) -
New Drug Access and Market Dynamism
Impact of Market Factors on New Drug Development in Japan
(No.43: Published in December 2008) -
Development Duration of New Drugs in Japan
Clinical Development Period and Approval Review Period
(No.42: Issued in September 2008) -
Internationalization of R&D Activities in the Pharmaceutical Industry
(No.41: Jul. 2008) -
Survey on Drug Lag in Japan Current Situation and Issues Based on Pharmaceutical Company Questionnaire
(No.40: Published in June 2008) -
Questionnaire Analysis of the Use of Foreign Clinical Trials in Drug Development in Japan
(No.39: June 2008) -
Clinical Data Package for New Drugs in Japan
(No.38, March 2008) -
Approval review period for new drugs in Japan
Survey in 2007
(No.37: Published in December 2007) -
Patient Satisfaction and Image of the Pharmaceutical Industry in Comparison of Patient Associations
Differences in Patient Attitudes by Disease and Medical Consumers in General
(No.36: Issued in April 2007) -
Duration of Approval Review for New Drugs in Japan (Items Approved from 1996 to 2005)
(No.35: Issued Dec. 2006) -
Patient Satisfaction and the Image of the Pharmaceutical Industry in an International Comparison
Factor Analysis of Medical and Drug Satisfaction and Image of the Pharmaceutical Industry
(No.34: Published November 2006) -
Postmarketing Clinical Research as a Condition for Approval
A Survey of Products Approved in 2000-2005
(No.33: Published in August 2006) -
Toward Further Dissemination of Superior Drug Therapy Toward Further Dissemination of Superior Drug Therapy
Current status and discussion of interferon therapy among hepatitis C virus-infected patients
(No.32: Published in August 2006) -
Time from the first global launch of a drug to its launch in each country
Toward improving access to medicines in Japan
(No.31: May 2006) -
Duration of Approval Review and Clinical Development of New Drugs in Japan
Survey of items approved in 2004
(No.30: Published in August 2005) -
Communication between Medical Consumers and Physicians
An Analysis of Patient Satisfaction from an Attitude Survey
(No.29: Issued in July 2005) -
NHI Drug Price System to Reflect the Value of New Drugs
Proposal for an Application Price Consultation System
(No.28: July 2005 issue) -
Impact of Technological Innovation on Drug Development
(No.27: June 2005 issue) -
Medical and Economic Effects of New Drug Introduction
Analysis of the effect of a cerebroprotective agent (edaravone) using medical accounting data, etc.
(No.26: June 2005 issue) -
Comparison of Approval Review of New Drugs in Japan and the U.S.
(No.25: May 2005 issue) -
Approval Review Periods for New Drugs in Japan
Survey of items approved in 2003
(No.24: Issued in November 2004) -
Japanese Pharmaceutical Companies in International Comparison
Focusing on Financial Data
(No.23: Published in October 2004) -
Government-Sponsored Cooperative Research in Japan:A Case Study of the Organization for Pharmaceutical Safety and Research (OPSR) Program
(No.22, published July 2004) July 2004) -
The Impact of Public Health Insurance Schemes on "Equity in Access to Health Care
A Panel Analysis with the Kakwani Index
(No.21: Published July 2004) -
The Value of Pharmaceuticals
(No.20: Published Jul. 2004) -
Pharmaceutical Price Calculation and Pharmacoeconomics.
Pathways to Application
(No.19: Issued in May 2004) -
Attitude Survey of Patients Participating in Clinical Trials
(No.18: Issued May 2004) -
Empowering Healthcare Consumers Based on Attitude Surveys
(No. 17: Issued May 2004) -
Government Funded Projects and Joint R&D
A Case Study of Pharmaceuticals Organization Funded Projects
(No.16: Published in February 2004) -
Research Productivity in the Japanese Pharmaceutical Industry Economies of Scale, Economies of Scope and Spillovers
（Research Productivity in the Japanese Pharmaceutical Economies of Scale, Economies of Scope and Spillovers (No.15: February 2004) -
Approval Review Period for New Drugs in Japan
(No.14: Published in December 2003) -
Ten Years of Pharmaceutical Companies from a Financial Data Perspective
Transformation of Profit Structure and Cost Structure
(No.13: Published in October 2003) -
Measuring Economic Profit Margins in the Japanese Pharmaceutical Industry
Comparison with other domestic industries, U.S. pharmaceutical industry, and other U.S. industries
(No.12: June 2003 issue) -
R&D Management of Japanese Drug Discovery Pharmaceutical Companies in the Era of Genomic Drug Discovery
(No.11: Published Sep. 2002) -
Characteristics of Japanese Biotech Ventures from the Perspective of Business Field, Investment Composition, Joint Research, and Patent Applications: A Research Network Perspective
(No.10: July 2002) -
R&D Productivity in the Japanese Pharmaceutical Industry
Economies of Scale, Economies of Scope, and Spillover Effects
(No.9: February 2002 issue) -
Duration and Cost of Drug Development
An Analysis Based on the Survey of New Drug Development
(No.8: Published in October 2001) -
An Economic Analysis of the Appropriateness of Cost Accounting Method as a Method for Calculating NHI Drug Prices for Innovative Drugs
(No.7, July 2001) -
Competitive Environment and R&D of Pharmaceutical Companies under Public Medical Insurance
(No.6: Issued in March 2001) -
Patent Indicators and Technological Innovation in the Japanese Pharmaceutical Industry
(No.5: Issued in Mar. 2000) -
Agenda for Economic Analysis of Pharmaceutical R&D
Preliminary Analysis on Survival Rate and Duration in the Development Process
(No.4: Published in Jan. 2000)